- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07750626
Effect of Vibration and ShotBlocker on Pain and Fear Levels During Intramuscular Injection in Children in the Emergency Department
The Effect of Vibration and ShotBlocker on Pain and Fear Levels During Intramuscular Injection in Children in the Emergency Department: A Randomized Controlled Trial
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Emergency departments are among the clinical areas where invasive procedures frequently encountered by children are performed. Intramuscular injections are one of the most common procedures performed on children in the emergency department, and they can cause pain and fear, leading to negative experiences for children. In the literature, it is stated that nurses should use pharmacological and non-pharmacological methods in pain and fear management in painful procedures. Evidence-based studies are needed to show the effectiveness of non-pharmacological methods in reducing pain during invasive procedures and to investigate the effects of easy-to-apply methods on pain.
This prospective study is planned as a randomized controlled study. The aim of this study is to investigate the effects of vibration and the ShotBlocker method on pain and fear levels in children during intramuscular injection in the emergency department.
The study will be conducted in three groups (Vibration, ShotBlocker, and Control), and a total of 120 children will be enrolled, with 40 participants in each group. The primary outcome will be pain intensity. The sample size was determined using an a priori power analysis performed with G*Power version 3.1.9.7. The calculation was based on a one-way analysis of variance (ANOVA) with three groups, an alpha level of 0.05, 80% statistical power (1-β = 0.80), and a Cohen's effect size (f) of 0.30. The analysis indicated that a minimum of 111 participants would be required. Considering potential participant attrition and missing data, the sample size was increased to 120 participants, with 40 children allocated to each group (Vibration Group, n = 40; ShotBlocker Group, n = 40; and Control Group, n = 40).
Data were collected through face-to-face interviews using three forms: the "Data Collection Form," the "Wong-Baker FACES Pain Scale," and the "Children's Fear Scale." Data Collection: Before starting the study, parents of children meeting the sample selection criteria will be briefly informed about the purpose of the study, and written consent will be obtained for their participation. Then, data collection tools will be administered. Forms will be collected through face-to-face interviews. After a child is selected, the nurse working at the institution will administer the intramuscular injection to the child, while routine injections will be given to the control group children. No intervention will be performed. The nurse will apply vibration to the vibration group children. In the vibration group, vibration will begin 30 seconds before the injection, and no vibration will be applied during the 10-second waiting phase while the nurse performs the intramuscular injection. In the shotblocker group children, the nurse will position the device between the injection site and the heel prick blood sample.
Shotblocker: This is a plastic device. No needle is inserted into the patient. The researcher will monitor the child's pain and fear levels during this time. Parents and observers will be asked to rate their fear/anxiety levels on the CFS scale before, during, and after the procedure, while children will be asked to do the same before and after. The child's post-procedure pain level (WB-FACES scale) will be assessed by the child themselves, as well as by the parent and observer. The scales will be evaluated independently and simultaneously, and the results will be recorded on a form.
No invasive procedure will be performed on the child. All these procedures will take approximately 5-10 minutes.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Selda ATES BESIRIK, PhD. Study Principal Investigator, Assist. Prof.
- Numero di telefono: +905543683323
- Email: seldaates07@gmail.com
Backup dei contatti dello studio
- Nome: Selda ATES BESIRIK, PhD.
- Email: seldaates07@gmail.com
Luoghi di studio
-
-
-
Burdur, Turchia (Türkiye)
- Reclutamento
- Burdur Mehmet Akif Ersoy University
-
Contatto:
- Selda ATES BESIRIK, PhD.
- Numero di telefono: +905543683323
- Email: seldaates07@gmail.com
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Bambino
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Volunteering of the child and parent to participate in the study,
- Children the ages between 5-10,
- Having intramuscular (IM) injection.
Exclusion Criteria:
- Communication problem,
- Children with any chronic illness,
- Taking any medication that has an analgesic effect at least 6 hours before applying.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Vibration Group
Vibration was applied to the children in this group before and during the intramuscular Injection procedure.
|
The vibration device was operated for 30 seconds with reference to previous studies.
While the vibration continued, the nurse with a needle.Then, the vibration device continued to work in the waiting phase for 10 seconds.
The vibration device was removed from routine intramuscular Injection procedure.
Altri nomi:
|
|
Sperimentale: Shotblocker Group
ShotBlocker was applied to the children in this group before and during the intramuscular Injection procedure.
|
The protruding surface of the Shotblocker was placed on the procedure site.
While applying pressure on the skin through the Shotblocker, the nurse performed with the needle through the opening in the center of the Shotblocker.
During the 10-second waiting phase, the Shotblocker was kept at the procedure site with the same pressure.
Then Shotblocker was removed from the skin and routine capillary intramuscular injection procedure was performed.
Altri nomi:
|
|
Nessun intervento: Control Group
In this group, child received routine intramuscular Injection procedure.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Scala di valutazione del dolore di Wong-Baker FACES
Lasso di tempo: Attraverso il completamento della procedura dolorosa, una media di 10 minuti
|
Nello studio, le valutazioni del livello del dolore, le autovalutazioni dei bambini, le valutazioni dei genitori e le valutazioni del ricercatore sono state effettuate utilizzando la scala WB-FACES.
Questa scala è stata sviluppata da Donna Wong e Connie Morain Baker nel 1988.
La scala è graduata tra 0-10 punti.
Una faccia sorridente all'estrema sinistra simboleggia "nessun dolore" (0 molto felice/nessun dolore) e il dolore aumenta da sinistra a destra.
D'altra parte, una faccia che piange all'estrema destra simboleggia "dolore insopportabile" (10 "fa più male").
Man mano che i numeri aumentano in questo sistema di punteggio, anche le espressioni facciali cambiano in riferimento a un aumento dei livelli di dolore.
|
Attraverso il completamento della procedura dolorosa, una media di 10 minuti
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Children's Fear Scale
Lasso di tempo: Through painful procedure completion, an average of 10 minutes.
|
CFS is used for measuring the child's anxiety level.
CFS is a scale which makes an evaluation from 0 to 4 consisting of five facial expressions drawn to show expressions that vary from neutral expression (0=no anxiety) to scared face (4=severe anxiety).
|
Through painful procedure completion, an average of 10 minutes.
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Selda A ATES BESIRIK, PhD., Burdur Mehmet Akif Ersoy University
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- GO 2026/2536
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
- ICF
- CODICE_ANALITICO
- RSI
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .